Apixaban, edoxaban and rivaroxaban but not dabigatran are associated with higher mortality compared to vitamin-K antagonists: A retrospective German claims data analysis.
bleeding
oral anticoagulation
overall survival
real‐world data
thromboembolic events
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
02 Sep 2024
02 Sep 2024
Historique:
medline:
2
9
2024
pubmed:
2
9
2024
entrez:
2
9
2024
Statut:
aheadofprint
Résumé
Vitamin-K antagonists (VKAs) have widely been replaced by non-VKA oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as VKA, instead of warfarin, the much longer-acting phenprocoumon is used, which was not compared to NOACs in clinical trials. Using administrative data from a large German health insurance, we included all anticoagulation-naïve patients with a first prescription of a NOAC or VKA between 2012 and 2020. We analysed overall survival, major adverse cardiac and cerebrovascular events, major thromboembolic events and major bleeding. Overall, 570,137 patients were included (apixaban: 26.9%, dabigatran: 4.6%, edoxaban: 8.8%, rivaroxaban: 39.1% and VKA: 20.7% of these 99.4% phenprocoumon). In the primary analysis using a 1:1 propensity score matching-cohort (PSM-cohort), a significantly higher overall mortality was found for apixaban, edoxaban and rivaroxaban (all p < 0.001) but not for dabigatran (p = 0.13) compared to VKA. In this PSM-cohort, 5-year mortality was 22.7% for apixaban versus 12.7% for VKA, 19.5% for edoxaban versus 11.4% for VKA, 16.0% for rivaroxaban versus 12.3% for VKA (all p < 0.001) and 13.0% for dabigatran versus 12.8% for VKA (p = 0.06). The observed effect was confirmed in sensitivity analyses using un-weighted and three different weighted Fine-Gray regression models on the basis of the entire cohort. In this large real-world analysis, apixaban, edoxaban and rivaroxaban, but not dabigatran, were associated with worse survival compared to VKA. These findings, consistent with a few other studies including phenprocoumon, cast profound doubts on the unreflected, general use of NOACs. Randomized trials should assess whether phenprocoumon might actually be superior to NOACs.
Sections du résumé
BACKGROUND
BACKGROUND
Vitamin-K antagonists (VKAs) have widely been replaced by non-VKA oral anticoagulants (NOACs). This includes Austria, Germany and Switzerland, where as VKA, instead of warfarin, the much longer-acting phenprocoumon is used, which was not compared to NOACs in clinical trials.
METHODS
METHODS
Using administrative data from a large German health insurance, we included all anticoagulation-naïve patients with a first prescription of a NOAC or VKA between 2012 and 2020. We analysed overall survival, major adverse cardiac and cerebrovascular events, major thromboembolic events and major bleeding.
RESULTS
RESULTS
Overall, 570,137 patients were included (apixaban: 26.9%, dabigatran: 4.6%, edoxaban: 8.8%, rivaroxaban: 39.1% and VKA: 20.7% of these 99.4% phenprocoumon). In the primary analysis using a 1:1 propensity score matching-cohort (PSM-cohort), a significantly higher overall mortality was found for apixaban, edoxaban and rivaroxaban (all p < 0.001) but not for dabigatran (p = 0.13) compared to VKA. In this PSM-cohort, 5-year mortality was 22.7% for apixaban versus 12.7% for VKA, 19.5% for edoxaban versus 11.4% for VKA, 16.0% for rivaroxaban versus 12.3% for VKA (all p < 0.001) and 13.0% for dabigatran versus 12.8% for VKA (p = 0.06). The observed effect was confirmed in sensitivity analyses using un-weighted and three different weighted Fine-Gray regression models on the basis of the entire cohort.
CONCLUSIONS
CONCLUSIONS
In this large real-world analysis, apixaban, edoxaban and rivaroxaban, but not dabigatran, were associated with worse survival compared to VKA. These findings, consistent with a few other studies including phenprocoumon, cast profound doubts on the unreflected, general use of NOACs. Randomized trials should assess whether phenprocoumon might actually be superior to NOACs.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 BARMER Institut für Gesundheitssystemforschung and The Author(s). Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Références
Zhu J, Alexander GC, Nazarian S, Segal JB, Wu AW. Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010–2017. Pharmacotherapy. 2018;38:907–920.
Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23:1612–1676.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström‐Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio‐Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74:104–132.
Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G‐J, Harjola V‐P, et al. 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41:543–603.
Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4:4693–4738.
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt‐Montoya S, Black SA, et al. Editor's Choice—European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg. 2021;61:9–82.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
Vinogradova Y, Coupland C, Hill T, Hippisley‐Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362:k2505.
Crocetti E, Cattaneo S, Bergamaschi W, De Servi S, Russo AG. Effectiveness and safety of non‐vitamin k oral anticoagulants in non‐valvular atrial fibrillation patients: results of a real‐world study in a metropolitan area of Northern Italy. J Clin Med. 2021;10:4536.
Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibrillation: a population‐based cohort study. Ann Intern Med. 2021;174:910–919.
Fawzy AM, Yang WY, Lip GY. Safety of direct oral anticoagulants in real‐world clinical practice: translating the trials to everyday clinical management. Expert Opin Drug Saf. 2019;18:187–209.
Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient‐level network meta‐analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145:242–255.
Jobski K, Hoffmann F, Herget‐Rosenthal S, Dörks M. Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. Br J Clin Pharmacol. 2018;84:590–601.
Haas S, Camm JA, Harald D, Steffel J, Virdone S, Pieper K, et al. GARFIELD‐AF: risk profiles, treatment patterns and 2‐year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clin Res Cardiol. 2023;112:759–771.
Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47:565–594.
Reinecke H, Unrath M, Freisinger E, Bunzemeier H, Meyborg M, Luders F, et al. Peripheral arterial disease and critical limb ischaemia: still poor outcomes and lack of guideline adherence. Eur Heart J. 2015;36:932–938.
Freisinger E, Koeppe J, Gerss J, Goerlich D, Malyar NM, Marschall U, et al. Mortality after use of paclitaxel‐based devices in peripheral arteries: a real‐world safety analysis. Eur Heart J. 2020;41:3732–3739.
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
Kuss O, Blettner M, Börgermann J. Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int. 2016;113:597–603.
Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:390–400.
Li L, Greene T. A weighting analogue to pair matching in propensity score analysis. Int J Biostat. 2013;9:215–234.
Marston XL, Wang R, Yeh YC, Zimmermann L, Ye X, Gao X, et al. Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: a real‐world cohort study. Int J Cardiol. 2022;346:93–99.
Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY. Comparative effectiveness and safety of non‐vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip GYH. Real‐world setting comparison of nonvitamin‐K antagonist oral anticoagulants versus vitamin‐K antagonists for stroke prevention in atrial fibrillation: a systematic review and meta‐analysis. Stroke. 2017;48:2494–2503.
Mueller S, Groth A, Spitzer SG, Schramm A, Pfaff A, Maywald U. Real‐world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset. Pragmat Obs Res. 2018;9:1–10.
Paschke LM, Klimke K, Altiner A, von Stillfried D, Schulz M. Comparing stroke prevention therapy of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation: a nationwide retrospective observational study. BMC Med. 2020;18:254.
Preinreich J, Sheikh Rezaei S, Mittlböck M, Greisenegger S, Reichardt B, Wolzt M. Oral anticoagulant therapy and outcome in patients with stroke. A retrospective nation‐wide cohort study in Austria 2012–2017. Pharmacoepidemiol Drug Saf. 2021;30:1332–1338.
Warkentin L, Hueber S, Deiters B, Klohn F, Kühlein T. Vitamin‐K‐antagonist phenprocoumon versus low‐dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real‐world analysis of German claims data. Thromb J. 2022;20:31.
Warkentin L, Klohn F, Deiters B, Kühlein T, Hueber S. Vitamin‐K‐antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real‐world analysis of German claims data. BMJ Open. 2023;13:e063490.
Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non‐vitamin K oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. Thromb Haemost. 2018;118:526–538.
Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagres N, et al. Initial apixaban dosing in patients with atrial fibrillation. Clin Cardiol. 2018;41:671–676.
Shen NN, Ferroni E, Amidei CB, Canova C, Peron V, Wang JL, et al. An updated pooled analysis of off‐label under and over‐dosed direct oral anticoagulants in patients with atrial fibrillation. Clin Appl Thromb Hemost. 2023;29:10760296231179439.
Hoffmann F, Icks A. Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health –Care Monitor. Gesundheitswesen. 2012;74:291–297.
Destatis ‐ Federal Statistical Office of Germany. Database of the Federal Statistical Office of Germany. Available from https://www‐genesis.destatis.de/genesis/online Accessed 7 May 2024.
Sarganas G, Knopf H, Grams D, Neuhauser HK. Trends in antihypertensive medication use and blood pressure control among adults with hypertension in Germany. Am J Hypert. 2016;29:104–113.
Heidemann C, Scheidt‐Nave C. Prevalence, incidence and mortality of diabetes mellitus in adults in Germany—a review in the framework of the diabetes surveillance. J Health Monit. 2017;2:98–121.
de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?‐a systematic review. Thromb Haemost. 2020;120:1323–1329.
Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123:1436–1450.
Schulman S. Advantages and limitations of the new anticoagulants. J Intern Med. 2014;275:1–11.
Kassenärztliche Bundesvereinigung. Direkte orale Antikoagulanzien. Berlin. 2020. Available from https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimitteltherapie/WA/Archiv/DOAK‐nv‐VHF.pdf Accessed 14 May 2024.
Dietrich F, Polymeris AA, Albert V, Engelter ST, Hersberger KE, Schaedelin S, et al. Intake reminders are effective in enhancing adherence to direct oral anticoagulants in stroke patients: a randomised cross‐over trial (MAAESTRO study). J Neurol. 2024;271:841–851.
Vrijens B, Heidbuchel H. Non‐vitamin K antagonist oral anticoagulants: considerations on once‐ vs. twice‐daily regimens and their potential impact on medication adherence. Europace. 2015:17:514–523.
Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey J‐Y, Schilling RJ, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace. 2014;16:6–14.
Jensen CF, Christensen TD, Maegaard M, Hasenkam JM. Quality of oral anticoagulant therapy in patients who perform self management: warfarin versus phenprocoumon. J Thromb Thrombolysis. 2009;28:276–281.
Prochaska JH, Göbel S, Keller K, Coldewey M, Ullmann A, Lamparter H, et al. Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine‐based coagulation service–results from the prospective, multi‐center, observational cohort study thrombEVAL. BMC Med. 2015;13:14.
Baker WL, Cios DA, Sander SD, Coleman CI. Meta‐analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244–252.
Lopes RD, Al‐Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380:1749–1758.
de Groot JR, Ruff CT, Murphy SA, Hamershock RA, Vehmeijer JT, Oude Ophuis AJM, et al. Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: a secondary analysis of the ENGAGE AF‐TIMI 48 study. Am Heart J. 2021;235:132–139.
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once‐daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127:224–232.
Eichler HG, Abadie E, Breckenridge A, Flamion B, Gustafsson LL, Leufkens H, et al. Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495–506.
Corrigan‐Curay J, Sacks L, Woodcock J. Real‐world evidence and real‐world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867–868.
McAlister FA, Garrison S, Kosowan L, Ezekowitz JA, Singer A. Use of direct oral anticoagulants in Canadian primary care practice 2010–2015: a cohort study from the canadian primary care sentinel surveillance network. J Am Heart Assoc. 2018;7:e007603.
Sugrue A, Sanborn D, Amin M, Farwati M, Sridhar H, Ahmed A, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Cardiol. 2021;144:52–59.
Rose AJ, Timbie JW, Setodji C, Friedberg MW, Malsberger R, Kahn KL. Primary care visit regularity and patient outcomes: an observational study. J Gen Intern Med. 2019;34:82–89.
Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, et al. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017;17:236.